Wordt geladen...
Ibrutinib-induced cardiomyopathy
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital...
Bewaard in:
| Gepubliceerd in: | J Community Hosp Intern Med Perspect |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6374917/ https://ncbi.nlm.nih.gov/pubmed/30788077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20009666.2018.1555432 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|